149 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 33538958 | Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group. | 2021 Feb 4 | 1 |
2 | 33985511 | Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy. | 2021 May 13 | 4 |
3 | 34211587 | External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry. | 2021 | 1 |
4 | 34268956 | Efficacy of trastuzumab combined with SOX or IP chemotherapy regimen in the treatment of advanced gastric cancer. | 2021 May-Jun | 2 |
5 | 34386088 | Anthelminthic niclosamide inhibits tumor growth and invasion in cisplatin-resistant human epidermal growth factor receptor 2-positive breast cancer. | 2021 Sep | 4 |
6 | 34729945 | HER2 targeting near-infrared photoimmunotherapy for a CDDP-resistant small-cell lung cancer. | 2021 Dec | 6 |
7 | 35070983 | Prediction of the Mechanisms by Which Quercetin Enhances Cisplatin Action in Cervical Cancer: A Network Pharmacology Study and Experimental Validation. | 2021 | 1 |
8 | 31790894 | Synergistic anticancer effect of combined use of Trichosanthes kirilowii with cisplatin and pemetrexed enhances apoptosis of H1299 non-small-cell lung cancer cells via modulation of ErbB3. | 2020 Jan | 1 |
9 | 32117718 | Caveolin-1 Promotes Chemoresistance of Gastric Cancer Cells to Cisplatin by Activating WNT/β-Catenin Pathway. | 2020 | 1 |
10 | 32269724 | Exploring cisplatin resistance in ovarian cancer through integrated bioinformatics approach and overcoming chemoresistance with sanguinarine. | 2020 | 1 |
11 | 32494981 | Comparison of S-1-cisplatin every 5 weeks with capecitabine-cisplatin every 3 weeks for HER2-negative gastric cancer (recurrent after S-1 adjuvant therapy or chemotherapy-naïve advanced): pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials. | 2020 Sep | 1 |
12 | 32943881 | Pathological Complete Response from Pyrotinib Combined with Trastuzumab, Paclitaxel and Cisplatin in a Postpartum Woman with HER2-Positive Locally Advanced Breast Cancer: A Case Report. | 2020 | 1 |
13 | 33042632 | Trastuzumab plus docetaxel and capecitabine as a first-line treatment for HER2-positive advanced gastric or gastroesophageal junction cancer: a phase II, multicenter, open-label, single-arm study. | 2020 | 2 |
14 | 30088161 | Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer. | 2019 Mar | 1 |
15 | 30711995 | Trastuzumab With S-1 Plus Cisplatin in HER2-positive Advanced Gastric Cancer Without Measurable Lesions: OGSG 1202. | 2019 Feb | 3 |
16 | 30799422 | A Rare Case of Mixed Adenoneuroendocrine Carcinoma (MANEC) of the Gastroesophageal Junction with HER2/neu Overexpression and Distinct Orbital and Optic Nerve Toxicity after Intravenous Administration of Cisplatin. | 2019 | 2 |
17 | 30809308 | Targeted Drug Delivery and Image-Guided Therapy of Heterogeneous Ovarian Cancer Using HER2-Targeted Theranostic Nanoparticles. | 2019 | 1 |
18 | 30856589 | Cisplatin-loaded PLGA nanoparticles for HER2 targeted ovarian cancer therapy. | 2019 Jun 1 | 2 |
19 | 30927036 | Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial. | 2019 Jun | 1 |
20 | 31102009 | Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer. | 2019 Nov | 1 |
21 | 31521263 | Doxorubicin/cisplatin co-loaded hyaluronic acid/chitosan-based nanoparticles for in vitro synergistic combination chemotherapy of breast cancer. | 2019 Dec 1 | 1 |
22 | 31772741 | Treatment of HER2+ metastatic salivary ductal carcinoma in a pregnant woman: a case report. | 2019 Oct | 1 |
23 | 32156946 | [Two Cases of Complete Response to Trastuzumab Combined with Chemotherapy for Recurrence of HER2-Positive Gastric Cancer]. | 2019 Dec | 1 |
24 | 26780095 | Complete and Durable Remission of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Urothelial Carcinoma Following Third-Line Treatment with Trastuzumab and Gemcitabine. | 2018 | 2 |
25 | 28343375 | FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation. | 2018 Jan | 1 |
26 | 29090377 | Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study. | 2018 Feb | 1 |
27 | 29174919 | Chemotherapy for alpha-fetoprotein producing gastric cancers expressing human epidermal growth factor receptor 2. | 2018 Apr | 1 |
28 | 29290024 | A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study). | 2018 Feb | 2 |
29 | 29434871 | Mechanisms for DNA-damaging agent-induced inactivation of ErbB2 and ErbB3 via the ERK and p38 signaling pathways. | 2018 Feb | 2 |
30 | 29451302 | Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in human epidermal growth factor receptor 2-positive advanced oesophagogastric cancer: A meta-analysis. | 2018 Jul 15 | 2 |
31 | 30145203 | Integrated proteomic and phosphoproteomic analyses of cisplatin-sensitive and resistant bladder cancer cells reveal CDK2 network as a key therapeutic target. | 2018 Nov 28 | 1 |
32 | 30692485 | [A Case of Hepatic Resection after Neoadjuvant Chemotherapy for Single Liver Metastasis from Gastric Cancer with Positive Human Epidermal Growth Factor Receptor 2]. | 2018 Dec | 2 |
33 | 28160563 | Tumor suppressor role of miR-3622b-5p in ERBB2-positive cancer. | 2017 Apr 4 | 1 |
34 | 28234911 | Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer. | 2017 | 1 |
35 | 28260018 | Effects of 5-fluorouracil, adriamycin and irinotecan on HSC-39, a human scirrhous gastric cancer cell line. | 2017 Apr | 1 |
36 | 28526406 | Trastuzumab emtansine suppresses the growth of HER2-positive small-cell lung cancer in preclinical models. | 2017 Jul 8 | 1 |
37 | 28850174 | Chemotherapy for advanced gastric cancer. | 2017 Aug 29 | 2 |
38 | 28913549 | Multicenter phase II study of capecitabine plus cisplatin as first-line therapy for human epidermal growth factor receptor 2-negative advanced gastric cancer: Yokohama Clinical Oncology Group Study YCOG1107. | 2017 Nov | 3 |
39 | 29108309 | Weekly paclitaxel and cisplatin as neoadjuvant chemotherapy with locally advanced breast cancer: a prospective, single arm, phase II study. | 2017 Oct 3 | 1 |
40 | 26846307 | Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition. | 2016 Feb 5 | 5 |
41 | 26893657 | Upregulation of microRNA-375 increases the cisplatin-sensitivity of human gastric cancer cells by regulating ERBB2. | 2016 Feb | 1 |
42 | 27002325 | A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer. | 2016 May | 2 |
43 | 27284358 | HER2-positive gastric cancer identified by serum HER2: A case report. | 2016 Jun | 1 |
44 | 27760940 | [A Case of HER2-Positive Advanced Gastric Cancer with Multiple Liver Metastases Effectively Treated with Trastuzumab, Capecitabine, and Cisplatin Combination Therapy]. | 2016 Oct | 2 |
45 | 25143433 | Constitutively active ErbB2 regulates cisplatin-induced cell death in breast cancer cells via pro- and antiapoptotic mechanisms. | 2015 Jan | 1 |
46 | 25624920 | Trastuzumab increases the sensitivity of HER2-amplified human gastric cancer cells to oxaliplatin and cisplatin by affecting the expression of telomere-associated proteins. | 2015 Feb | 2 |
47 | 25661103 | Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. | 2015 Mar | 1 |
48 | 25744576 | Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. | 2015 Apr | 1 |
49 | 25812508 | [A case of HER2-positive advanced gastric cancer successfully treated via capecitabine, cisplatin, and trastuzumab combination chemotherapy]. | 2015 Mar | 3 |
50 | 26047983 | Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer. | 2015 Oct | 1 |